These 2 Stocks Have Run Circles Around the Magnificent Seven This Year, and Wall Street Says There Is More Upside Ahead
Innovation pays off.
The Magnificent Seven, a group of tech companies, have experienced mixed and volatile performances this year. Two lesser-known stocks, Revolution Medicines (RVMD) and Oruka Therapeutics (ORKA), have outperformed the Magnificent Seven and still have significant upside potential according to Wall Street price targets. Revolution Medicines recently received approval for Rasonque, a treatment for metastatic pancreatic cancer, showing promising results in a Phase 3 study with a median overall survival of 13.2 months compared to 6.7 months for standard chemotherapy.
Analysts project $15.1 billion in peak revenue by 2034 for pancreatic cancer alone. However, the stock may be overvalued at current levels, and there is a risk of significant decline if there are setbacks. Oruka Therapeutics, on the other hand, has a promising candidate in its pipeline, ORKA-001, for plaque psoriasis. The Phase 2a study shows strong efficacy, and the medicine could be administered once or twice a year.
With an average price target of $155, indicating a 95% upside from current levels, Oruka Therapeutics is riskier due to the lack of Phase 3 trials and the volatile nature of the biotech industry.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.